Log In
Print this Print this

MabThera, Rituxan, rituximab (R105, RG105)

Also known as: IDEC-C2B8

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionChimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionBinds CD20; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today